We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Anna MacDonald

Anna MacDonald

Science Writer

Contact Us


After obtaining a first-class honours degree in biological sciences from the University of East Anglia, Anna worked as a scientific conference producer before joining Technology Networks. As part of her role, Anna helps to coordinate coverage, working with key opinion leaders from industry and academia to produce content across all communities.


Latest Content
Probing the Proteome With Engineered Nanoparticles content piece image
Industry Insight

Probing the Proteome With Engineered Nanoparticles

In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.
Identifying Risk Factors for Long COVID With Single-Cell Proteomics content piece image
Industry Insight

Identifying Risk Factors for Long COVID With Single-Cell Proteomics

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.
Using Bioelectronic Assays To Advance Drug Discovery for Neurological Diseases content piece image
Industry Insight

Using Bioelectronic Assays To Advance Drug Discovery for Neurological Diseases

In this interview, Jim Ross highlights several recent examples of how bioelectronic assays are helping to advance drug discovery for neurological diseases ranging from pediatric epilepsy to Burning Man Syndrome.
Developing Novel Liquid Biopsy Oncology Tests content piece image
Industry Insight

Developing Novel Liquid Biopsy Oncology Tests

In this interview, Aiguo Zhang discusses some of the technologies that DiaCarta has developed within the liquid biopsy space and shares his thoughts on what the future may hold for the field.
Time for Proteomics To Shine content piece image
Industry Insight

Time for Proteomics To Shine

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.
Driving Change in Rare Disease Diagnostics  content piece image
Industry Insight

Driving Change in Rare Disease Diagnostics

In this two-part interview series, Technology Networks delves deeper into the diagnostic odyssey many rare disease patients face and explores current efforts to develop improved therapies for these patients.
Moving Towards the Next Era in Rare Disease Therapeutics content piece image
Industry Insight

Moving Towards the Next Era in Rare Disease Therapeutics

In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.
Targeting EBV-Infected Cells To Treat Multiple Sclerosis content piece image
Industry Insight

Targeting EBV-Infected Cells To Treat Multiple Sclerosis

Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.
Streamlining Urinalysis Workflows content piece image
Industry Insight

Streamlining Urinalysis Workflows

To learn more about the impact of manual inspection on urinalysis labs and how automated solutions such as the DxU Iris are helping to streamline workflows, Technology Networks spoke to Jose Crespo, senior director sales and marketing Europe, Beckman Coulter.
Women in Science: Perspectives From Industry content piece image
Industry Insight

Women in Science: Perspectives From Industry

In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.
Advertisement